Pelthos Therapeutics is a Durham, North Carolina-based specialty bio-pharmaceutical organization dedicated to delivering innovative therapies for patients facing unmet treatment needs.

We focus on commercializing safe and efficacious products, most notably ZELSUVMI™ (berdazimer) topical gel, 10.3%, approved by the U.S. FDA for the treatment of molluscum contagiosum.

Leveraging our team’s expertise in nitric oxide-based technology and the NITRICIL™ platform, we’re committed to advancing dermatology and addressing common skin conditions. Our recent acquisitions of Xepi® and Xeglyze® further expand our portfolio, bringing new solutions to patients.

Pelthos Therapeutics is driven by a mission to improve patient outcomes and provide accessible, high-quality treatments.

ZELSUVMI™ | Pelthos Therapeutics

Product description

Pelthos Therapeutics Durham, United States (US)

Price: N/A

Pelthos Therapeutics
Durham, United States (US)